Mark Agulnik, MD

Mark Agulnik, MD, is a medical oncologist with the USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC

Articles

Moving the Needle in Undifferentiated Pleomorphic Sarcoma: Conclusions

April 20th 2025

In this episode, experts highlight the key takeaways from the Stand Up to Cancer SARC 032 study and its clinical implications.

Moving the Needle in Undifferentiated Pleomorphic Sarcoma: Multidisciplinary Collaboration

April 19th 2025

In this episode, experts discuss the landmark SARC 032 study, highlighting the importance of multidisciplinary collaboration.

Moving the Needle in Undifferentiated Pleomorphic Sarcoma: Impact of Immunotherapy on Surgical Planning

April 18th 2025

In this episode, experts discuss the impact of neoadjuvant radiation and immunotherapy on surgical planning in patients with soft tissue sarcomas.

Moving the Needle in Undifferentiated Pleomorphic Sarcoma: Surgical Oncology Goals

April 17th 2025

In this episode, experts shed light on the surgical approach to soft tissue sarcomas.

Moving the Needle in Undifferentiated Pleomorphic Sarcoma: Radiation Oncology and Immune Stimulation

April 16th 2025

In this episode, experts discuss the potential of radiation therapy to enhance immune response in soft tissue sarcomas.

Moving the Needle in Undifferentiated Pleomorphic Sarcoma: Trial Design and Key Data

April 15th 2025

In this episode, experts discuss the rationale behind the combined treatment in the Stand Up to Cancer SARC 032 trial.

Moving the Needle in Undifferentiated Pleomorphic Sarcoma: Overview of Paradigm

April 14th 2025

In this episode, experts discuss the latest advancements in the multimodal treatment of undifferentiated pleomorphic sarcoma of the extremities.

Dr Agulnik on the Evolving Management of Heterogenous Disease in GIST

July 16th 2024

Mark Agulnik, MD, discusses the evolving management of heterogeneous disease types in gastrointestinal stromal tumors.

Agulnik Highlights Key Updates in GIST Research and Management

June 24th 2024

Dr Agulnik spotlights key updates from across the GIST landscape ahead of GIST Awareness Day on July 13.

Future Perspectives on the Treatment of Desmoid Tumors

February 19th 2024

A panel of oncology experts provides insights into the future outlook for desmoid tumor treatment, discussing anticipated developments in the field.

Nirogacestat's Impact on the Future Treatment of Desmoid Tumors

February 19th 2024

Expert oncologists discuss the recent approval of nirogacestat for the treatment of desmoid tumors and explore its impact on clinical practice and the future treatment landscape.

Impact of Nirogacestat on Pain, Quality of Life, and Fertility in Patients with Desmoid Tumors

February 12th 2024

A panel of oncology experts discuss the impact of nirogacestat on pain symptoms and quality of life indicators for individuals with desmoid tumors, as well as the possible effects on ovarian function.

DeFi: Nirogacestat in Patients with Progressing Desmoid Tumors

February 12th 2024

Jonathan Trent, MD, PhD, discusses the rationale and design of the DeFi study, instrumental in the FDA approval of nirogacestat, and explores key efficacy and safety findings from this research.

Targeting NOTCH Pathway Signaling with Nirogacestat

February 5th 2024

Mark Agulnik, MD, examines the mechanism of action of nirogacestat, emphasizing the impact of ϒ-secretase inhibition on NOTCH pathway signaling.

Desmoid Tumors in Women: Special Considerations for Pregnancy and Contraception

February 5th 2024

A panel of oncology experts provides insights into the management of desmoid tumors in women, focusing on special considerations for pregnancy and contraception.

The Role of Supportive Care Measures in Patients with Desmoid Tumors

January 29th 2024

Jonathan Trent, MD, PhD, discusses the role of approaches using low-dose and conventional chemotherapy, emphasizing key consideration factors for patient selection.

Approaches to Systemic Therapy in Desmoid Tumors: The Role of Chemotherapy

January 29th 2024

Mark Agulnik, MD, gives a summary of approaches to systemic therapy in the management of desmoid tumors, highlighting the diminishing role of chemotherapy and the shift towards targeted therapies.

Treatment Strategies Using Radiotherapy or Other Locoregional Approaches in Desmoid Tumors

January 22nd 2024

Chandrajit Raut, MD, explores the role of radiotherapy and other locoregional strategies in desmoid tumor management, highlighting the emerging role of cryoablation and HIFU.

The Evolving Role of Surgery in the Management of Desmoid Tumors

January 22nd 2024

Chandrajit Raut, MD, shares expert insights into the evolving role of surgical strategies for desmoid tumor management, emphasizing essential factors in patient selection.

Active Surveillance in Frontline Management of Desmoid Tumors

January 15th 2024

A panel of oncology experts examine the significance of employing active surveillance as a primary strategy in the treatment of desmoid tumors, providing expert insights into this approach.